Oramed Pharmaceuticals' Earnings: Uncovering Hidden Warnings

Oramed Pharmaceuticals reported decent statutory profit but investors are disappointed due to a high accrual ratio of 1.35, indicating a negative impact on future earnings. The company had negative free cash flow of $11m and its profit was boosted by unusual items worth $65m in the last twelve months. This suggests that the profit may not be sustainable.